Search

Your search keyword '"Ray-Coquard, Isabelle"' showing total 2,210 results

Search Constraints

Start Over You searched for: Author "Ray-Coquard, Isabelle" Remove constraint Author: "Ray-Coquard, Isabelle"
2,210 results on '"Ray-Coquard, Isabelle"'

Search Results

101. Data from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer

102. Supplementary Appendix S1 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer

103. TP021/#1540 Reframe-O1/ENGOT-OV79/GOG-3086: a phase 2/3 open-label study evaluating the efficacy and safety of luveltamab tazevibulin versus investigator’s choice chemotherapy in relapsed platinum-resistant EOC expressing folate receptor-alpha

104. PO004LBA/#1515 Efficacy and safety of avutometinib + defactinib in recurrent low-grade serous ovarian cancer following prior systemic therapy

106. Connecting the changing metallomic spectrum and survival in sarcoma: a pilot study

107. Supplementary Data 1 from Molecular Results and Potential Biomarkers Identified from the Phase 3 MILO/ENGOT-ov11 Study of Binimetinib versus Physician Choice of Chemotherapy in Recurrent Low-Grade Serous Ovarian Cancer

108. Data from Molecular Results and Potential Biomarkers Identified from the Phase 3 MILO/ENGOT-ov11 Study of Binimetinib versus Physician Choice of Chemotherapy in Recurrent Low-Grade Serous Ovarian Cancer

109. Low-Grade Uterine Leiomyosarcoma Is Highly Sensitive to Hormonal Treatment

110. European multidisciplinary tumor boards support cross-border networking and increase treatment options for patients with rare gynecological tumors

113. Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial

114. Endometrial cancer

116. Determinants of the access to remote specialised services provided by national sarcoma reference centres

118. “Chronic fatigue, quality of life and long-term side-effects of chemotherapy in patients treated for non-epithelial ovarian cancer: national case-control protocol study of the GINECO-Vivrovaire rare tumors INCa French network for rare malignant ovarian tumors”

119. Clinical factors associated with prolonged response and survival under olaparib as maintenance therapy in BRCA mutated ovarian cancers

121. Anti-Angiopoietin Therapy With Trebananib for Recurrent Ovarian Cancer (TRINOVA-1)

122. Pazopanib or methotrexate–vinblastine combination chemotherapy in adult patients with progressive desmoid tumours (DESMOPAZ): a non-comparative, randomised, open-label, multicentre, phase 2 study

123. Texte court rédigé à partir de la recommandation nationale de bonnes pratiques cliniques « Conduites à tenir initiales devant des patientes atteintes d’un cancer épithélial de l’ovaire » élaborée par FRANCOGYN, CNGOF, SFOG, GINECO-ARCAGY et labélisée par l’INCa »

124. Non-pegylated liposomal doxorubicin (NPLD, Myocet®) + carboplatin in patients with platinum sensitive ovarian cancers: A ARCAGY-GINECO phase IB-II trial

126. Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial

127. HE4 and CA-125 kinetics to predict outcome in patients with recurrent epithelial ovarian carcinoma: the META4 clinical trial.

128. Role of gene sequencing in classifying struma ovarii: BRAF p.G469A mutation and TERT promoter alterations favour malignant struma ovarii.

129. Role of gene sequencing in classifying struma ovarii: BRAF p.G469A mutation and TERT promoter alterations favour malignant struma ovarii

130. Gestational choriocarcinoma

131. #24 A phase 2 study (GOG-3084) OF ADP-A2M4CD8 TCR T-cell therapy, alone or in combination with nivolumab, in patients with recurrent ovarian cancers

132. Normalized LST Is an Efficient Biomarker for Homologous Recombination Deficiency and Olaparib Response in Ovarian Carcinoma

133. #66 Survival of PARP inhibitor (PARPi) naïve ovarian cancer patients with a BRCA-mutation receiving maintenance olaparib after chemotherapy for first recurrence. An exploratory analysis of the solo2/engot-ov21 trial

134. #676 Prognostic value of immune infiltrate in high-grade serous ovarian carcinoma according to platinum-sensitivity/resistance status

135. #201 Real world evidence (RWE) on the efficacy of chemotherapy after progression during or following PARPi exposure in ovarian cancer. a multicentre, international study

136. #528 Efficacy of subsequent chemotherapy followed by PARP inhibitor maintenance in patients with advanced ovarian cancer in the phase III PAOLA-1/ENGOT-Ov25 trial

139. Low-grade serous ovarian cancer: expert consensus report on the state of the science

140. Molecular Results and Potential Biomarkers Identified from the Phase 3 MILO/ENGOT-ov11 Study of Binimetinib versus Physician Choice of Chemotherapy in Recurrent Low-Grade Serous Ovarian Cancer

141. ESR1 Rearrangement as a Diagnostic and Predictive Biomarker in Uterine Tumor Resembling Ovarian Sex Cord Tumor: A Report of Four Cases

142. Investigational drugs for recurrent or primary advanced metastatic cervical cancer: what is in the clinical development pipeline?

149. Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2

150. Maintenance olaparib plus bevacizumab in patients with newly diagnosed advanced high-grade ovarian cancer: Main analysis of second progression-free survival in the phase III PAOLA-1/ENGOT-ov25 trial

Catalog

Books, media, physical & digital resources